ClinicalTrials.gg

Program

BI 3000202

A development code.

Its studies are mostly in Lupus Erythematosus, Systemic, led by Boehringer Ingelheim.

Furthest: phase 2, since Feb 9, 20267 company-led studies, 2 open or runningNext primary completion: Feb 21, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim72 open or runningphase 2since Feb 9, 2026Jul 7, 2023Feb 21, 2027phase 1 · NCT07774325

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 7, 2023First study: phase 1 study in HealthyFirst studyNCT05945888 · 68 enrolled · Germany
  2. Mar 18, 2024Phase 1 study in HealthyNCT06327256 · 40 enrolled · Belgium
  3. Oct 9, 2025Phase 1 study in HealthyNCT07215260 · 14 enrolled · Germany
  4. Nov 27, 2025Phase 1 study in HealthyNCT07273474 · 12 enrolled · Netherlands
  5. Feb 9, 2026Phase 2 study in Lupus Erythematosus, SystemicPhase 2 reachedNCT07409181 · 405 planned · United States, Argentina, Australia and more
  6. Mar 17, 2026Phase 1 study in HealthyNCT07486102 · 34 enrolled · United States
  7. Aug 17, 2026Phase 1 study in HealthyNCT07774325 · 10 enrolled · Germany
  8. Nov 13, 2026Primary completion moved from 2026-12-06 to 2029-12-10Date moved laterphase 1 · +36 months · NCT06878365

Ahead

  1. Feb 21, 2027Primary completion: phase 1 study in HealthyNCT07774325
  2. Feb 4, 2029Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07409181

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07774325Healthy · Germany1Active, not recruitingFeb 21, 202710
NCT07486102Healthy · United States1CompletedOct 30, 202634
NCT07409181Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2RecruitingFeb 4, 2029405
NCT07273474Healthy · Netherlands1CompletedMar 5, 202612
NCT07215260Healthy · Germany1CompletedDec 7, 202514
NCT06327256Healthy · Belgium1CompletedSep 27, 202440
NCT05945888Healthy · Germany1CompletedNov 13, 202368

How it is read

Names in the registry

  • “BI 3000202”, 7 entries

Codes read as this program: BI3000202.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.